Summary
11.90
-0.19
(-1.57%)
08/13/2026
Intellia Therapeutics, Inc. (NTLA)Key Facts
Performance
Historical returns1D
-1.57%
1W
7.56%
1M
-7.14%
3M
-13.58%
6M
4.04%
1Y
11.33%
5Y
-92.46%
Snapshot
Key statisticsClose
11.90
Change
-0.19
Change %
-1.57%
Open
12.04
Day Range
11.83 – 12.18
Volume
1,980,243
Avg Vol (20d)
3,662,021
Rel Vol
0.54x
52W Range
7.95 - 28.25
vs 52W High
-57.88%
vs 52W Low
49.69%
Gap
-0.08
Market Cap
USD 1.06B
Beta
2.11
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
Notable Price Movement
Historical returnsAug 13
2026
$11.90 1.57%Latest
Intellia Therapeutics fell 1.57% to $11.90, though on light volume (0.5× the 20-day average). This was largely stock-specific: the S&P 500 gained 0.64% while Healthcare peers (XLV) rose 0.03% that session, leaving about 1.6 points of the move unexplained by its sector. The move left the stock 57.5% below its 52-week high.
Aug 10
2026
$12.02 0.67%Earnings
Intellia Therapeutics rose 0.67% to $12.02. Shares marked a 3rd consecutive advance. It came 2 sessions after the Q2 2026 print.
Aug 7
2026
$11.94 6.23%Earnings
Intellia Therapeutics rose 6.23% to $11.94, its biggest one-day gain in 2 months. This was largely stock-specific: the S&P 500 gained 0.57% while Healthcare peers (XLV) rose 0.58% that session, leaving about 5.0 points of the move unexplained by the market after adjusting for a 2.11 beta. Shares opened with a 6.58% gap up and reclaimed their 20-day moving average. It came 1 session after the Q2 2026 print.
Aug 6
2026
$11.24 2.46%Earnings
Intellia Therapeutics rose 2.46% to $11.24. This was largely stock-specific: the S&P 500 fell 0.16% while Healthcare peers (XLV) rose 0.18% that session, leaving about 2.3 points of the move unexplained by its sector. Shares opened with a 2.42% gap down and reversed through the session and closed near the session high (88% of the day's range). This was the first session after Q2 2026 results: EPS of $-0.80 vs $-0.80 expected (a miss) and revenue of $7.7M vs $13.0M (a miss).
Aug 4
2026
$11.32 5.11%
Intellia Therapeutics rose 5.11% to $11.32, its biggest one-day gain in 2 months. The move was broadly in line with the wider market — the S&P 500 gained 1.80% while Healthcare peers (XLV) fell 0.09% the same session — so little of it was company-specific. Shares opened with a 1.02% gap up and closed near the session high (98% of the day's range).
Jul 16
2026
$11.86 9.05%
Intellia Therapeutics fell 9.05% to $11.86, its biggest one-day drop in 3 months and a 1.6σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 fell 0.54% while Healthcare peers (XLV) rose 2.22% that session, leaving about 7.9 points of the move unexplained by the market after adjusting for a 2.11 beta. Shares opened with a 4.68% gap down.
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 2× | -1.57% |
| 1-Month | 3× | -1.57% |
| 3-Month | 14× | -33.30% |
| 6-Month | 14× | -33.30% |
| YTD | 17× | -33.30% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 17× | -57.47% |
| 2-Year | 10× | -57.47% |
| 3-Year | 0× | -70.26% |
| 5-Year | 2× | -93.27% |
| 10-Year | 38× | -93.27% |
Financial SnapshotFY 2025
Full financialsRevenue
USD 67.67M
+16.9% YoY
Net Income
-USD 519.02M
+0.0% YoY
EPS
-3.81
-27.4% YoY
Gross Margin
76.5%
Operating Margin
-651.7%
Net Margin
-767.0%
EBITDA
-USD 396.77M
Free Cash Flow
-USD 354.66M
-524.1% margin
ROE
-77.3%
ROA
-61.6%
Debt / Equity
0.14x
net debt -USD 62.14M
Cash & Equiv.
USD 155.46M
Fundamental Ratings
MainC
RecommendedSell
DCFNeutral
ROEStrong Sell
ROAStrong Sell
Debt/EquityNeutral
P/EStrong Sell
P/BSell
Latest Earnings
- NTLA reported last earnings on 2026-08-06.
- EPS of $-0.8 vs $-0.79927 estimated — surprise $-0.00.
- Revenue of $8M vs $13M estimated — surprise $-5M.
News
All newsIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to...
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
Intellia Therapeutics Q2 Earnings Call Highlights
Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.
Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.99 per share a year ago.
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the second...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Hold” by Brokerages
Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-three research firms that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a sell rating, nine have...
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August...
Amova Asset Management Americas Inc. Reduces Stake in Intellia Therapeutics, Inc. $NTLA
Amova Asset Management Americas Inc. cut its position in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 10.0% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,973,061 shares of the company's stock after selling 219,400 shares...
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
It might pull it off, provided several things fall right in place.
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FDA approval of Yartemlea and a significant development deal with Novo Nordisk.
Dow Extends Record Run as Fed Decision Looms
Stocks are mixed, with the Dow Jones Industrial Average (DJI) trading at fresh record highs once again
This Stock Is Up 58% This Year. Is It too Late to Buy?
There could be additional catalysts for this drugmaker over the next year.
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.